157 related articles for article (PubMed ID: 31709853)
81. Cost-utility analysis of aprepitant for patients who truly need it in Japan.
Tsukiyama I; Ando M; Tsukiyama S; Takeuchi M; Ejiri M; Kurose Y; Saito H; Arakawa I; Inoue T; Yamaguchi E; Kubo A
Support Care Cancer; 2019 Oct; 27(10):3749-3758. PubMed ID: 30710243
[TBL] [Abstract][Full Text] [Related]
82. Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single-center review.
Kanukollu S; Spatz K; Lavery JA; Bender JG; Mauguen A; Mathew S
Pediatr Blood Cancer; 2024 Apr; 71(4):e30882. PubMed ID: 38267822
[TBL] [Abstract][Full Text] [Related]
83. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F; Kraft WK
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
[TBL] [Abstract][Full Text] [Related]
84. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.
Langford P; Chrisp P
Core Evid; 2010 Oct; 5():77-90. PubMed ID: 21042544
[TBL] [Abstract][Full Text] [Related]
85. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.
Navari RM; Schwartzberg LS
Onco Targets Ther; 2018; 11():6459-6478. PubMed ID: 30323622
[TBL] [Abstract][Full Text] [Related]
86. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Gilmore J; Bernareggi A
J Clin Pharmacol; 2019 Apr; 59(4):472-487. PubMed ID: 30412271
[TBL] [Abstract][Full Text] [Related]
87. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.
Celio L; Ricchini F; De Braud F
Patient Prefer Adherence; 2013; 7():391-400. PubMed ID: 23687442
[TBL] [Abstract][Full Text] [Related]
88. The next generation of antiemetics for the management of postoperative nausea and vomiting.
Tan HS; Dewinter G; Habib AS
Best Pract Res Clin Anaesthesiol; 2020 Dec; 34(4):759-769. PubMed ID: 33288125
[TBL] [Abstract][Full Text] [Related]
89. Aprepitant: drug-drug interactions in perspective.
Aapro MS; Walko CM
Ann Oncol; 2010 Dec; 21(12):2316-2323. PubMed ID: 20488873
[TBL] [Abstract][Full Text] [Related]
90. The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting.
Palli SR; Grabner M; Quimbo RA; Rugo HS
Cancer Manag Res; 2015; 7():175-88. PubMed ID: 26124681
[TBL] [Abstract][Full Text] [Related]
91. Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.
Edwards JK; Bossaer JB; Lewis PO; Sant A
J Oncol Pharm Pract; 2020 Jun; 26(4):809-813. PubMed ID: 31446866
[TBL] [Abstract][Full Text] [Related]
92. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Johnson B; Adams L; Lu E; Zhang K; Lebowitz P; Lates C; Blum R
Support Care Cancer; 2009 Sep; 17(9):1177-85. PubMed ID: 19205755
[TBL] [Abstract][Full Text] [Related]
93. Safety of Polysorbate 80 in the Oncology Setting.
Schwartzberg LS; Navari RM
Adv Ther; 2018 Jun; 35(6):754-767. PubMed ID: 29796927
[TBL] [Abstract][Full Text] [Related]
94. Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron.
Ottoboni T; Lerner L; Santhouse A
Drug Des Devel Ther; 2021; 15():2519-2527. PubMed ID: 34163138
[TBL] [Abstract][Full Text] [Related]
95. Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Tyler T; Schultz A; Venturini A; Giuliano C; Bernareggi A; Spezia R; Voisin D; Stella V
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1405-1418. PubMed ID: 36263927
[TBL] [Abstract][Full Text] [Related]
96. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist.
Grélot L; Dapzol J; Estève E; Frugière A; Bianchi AL; Sheldrick RL; Gardner CJ; Ward P
Br J Pharmacol; 1998 Aug; 124(8):1643-50. PubMed ID: 9756379
[TBL] [Abstract][Full Text] [Related]
97. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
[TBL] [Abstract][Full Text] [Related]
98. Aprepitant and fosaprepitant use in children and adolescents at an academic medical center.
Shillingburg A; Biondo L
J Pediatr Pharmacol Ther; 2014 Apr; 19(2):127-31. PubMed ID: 25024673
[TBL] [Abstract][Full Text] [Related]
99. Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.
Zhang ZY; Wang J; Kansra V; Wang X
Invest New Drugs; 2019 Feb; 37(1):139-146. PubMed ID: 30032410
[TBL] [Abstract][Full Text] [Related]
100. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
